Moreover, we have demonstrated that PCa patients with high T cell immunity to the native HER-2/neu(776–790) polypeptide had better clinical outcomes when treated with a modified HER-2/neu(776–790) polypeptide vaccine than patients with no or low pre-existing immunity [21,32]. The gene discussed is ERBB2; the disease is posterior cortical atrophy.